Artemis Investment Management LLP Purchases 42,118 Shares of Repligen Co. (NASDAQ:RGEN)

Artemis Investment Management LLP raised its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 48.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 129,927 shares of the biotechnology company’s stock after acquiring an additional 42,118 shares during the quarter. Artemis Investment Management LLP owned approximately 0.23% of Repligen worth $19,336,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Diversified Trust Co boosted its holdings in Repligen by 255.0% during the third quarter. Diversified Trust Co now owns 10,469 shares of the biotechnology company’s stock worth $1,558,000 after purchasing an additional 7,520 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Repligen by 24.0% during the 3rd quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company’s stock worth $88,000 after buying an additional 115 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Repligen by 131.3% in the 3rd quarter. SG Americas Securities LLC now owns 6,520 shares of the biotechnology company’s stock valued at $970,000 after acquiring an additional 3,701 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in shares of Repligen in the 2nd quarter valued at about $106,000. Finally, Dana Investment Advisors Inc. increased its position in shares of Repligen by 45.7% in the second quarter. Dana Investment Advisors Inc. now owns 6,071 shares of the biotechnology company’s stock valued at $765,000 after acquiring an additional 1,903 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of RGEN stock opened at $135.02 on Wednesday. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a market capitalization of $7.54 billion, a price-to-earnings ratio of 540.08, a PEG ratio of 4.24 and a beta of 0.95. The company has a 50-day simple moving average of $149.19 and a 200 day simple moving average of $150.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.53 earnings per share. On average, sell-side analysts predict that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of analyst reports. Guggenheim began coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.